Nothing Special   »   [go: up one dir, main page]

NO20092102L - Krystallinformer av aliskiren hemifumarat - Google Patents

Krystallinformer av aliskiren hemifumarat

Info

Publication number
NO20092102L
NO20092102L NO20092102A NO20092102A NO20092102L NO 20092102 L NO20092102 L NO 20092102L NO 20092102 A NO20092102 A NO 20092102A NO 20092102 A NO20092102 A NO 20092102A NO 20092102 L NO20092102 L NO 20092102L
Authority
NO
Norway
Prior art keywords
informer
crystal
aliskiren hemifumarate
crystal forms
preparation
Prior art date
Application number
NO20092102A
Other languages
English (en)
Inventor
Stephanie Monnier
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37907983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092102(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092102L publication Critical patent/NO20092102L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives krystallformer av aliskiren hemifumarat og forskjellige utførelsesformer relatert dertil, for eksempel farmasøytiske preparater, fremgangsmåter for fremstilling av krystallformene, farmasøytiske anvendelser og lignende. Krystallformene har spesielt fordelaktige egenskaper, for eksempel er det nyttige ved fremstilling av blodtrykkssenkende, fannasøytiske preparater og lignende.
NO20092102A 2006-11-07 2009-05-28 Krystallinformer av aliskiren hemifumarat NO20092102L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123642 2006-11-07
PCT/EP2007/009573 WO2008061622A1 (en) 2006-11-07 2007-11-05 Crystalline forms of aliskiren hemifumarate

Publications (1)

Publication Number Publication Date
NO20092102L true NO20092102L (no) 2009-07-30

Family

ID=37907983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092102A NO20092102L (no) 2006-11-07 2009-05-28 Krystallinformer av aliskiren hemifumarat

Country Status (25)

Country Link
US (1) US8119841B2 (no)
EP (1) EP2079463A1 (no)
JP (1) JP2010508370A (no)
KR (1) KR20090083918A (no)
CN (1) CN101594857B (no)
AR (1) AR063560A1 (no)
AU (1) AU2007323465B2 (no)
BR (1) BRPI0718546A2 (no)
CA (1) CA2668828A1 (no)
CL (1) CL2007003194A1 (no)
CO (1) CO6180428A2 (no)
EC (1) ECSP099385A (no)
GT (1) GT200900116A (no)
IL (1) IL198470A0 (no)
MA (1) MA30921B1 (no)
MX (1) MX2009004885A (no)
MY (1) MY148758A (no)
NO (1) NO20092102L (no)
NZ (1) NZ577320A (no)
PE (2) PE20081157A1 (no)
RU (1) RU2466982C2 (no)
TN (1) TN2009000174A1 (no)
TW (1) TW200827326A (no)
WO (1) WO2008061622A1 (no)
ZA (1) ZA200902941B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029083A1 (en) * 2007-11-13 2012-02-02 Teva Pharmaceutical Industries, Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
WO2009094360A1 (en) 2008-01-23 2009-07-30 Novartis Ag Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
SI2676953T1 (sl) * 2008-12-18 2017-07-31 Novartis Ag Hemifumaratna sol 1-(4-(1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil)-2-etil- benzil)-azetidin-3-karboksilne kisline za uporabo v zdravljenju z limfociti posredovanih bolezni
JP2011526937A (ja) * 2009-02-05 2011-10-20 テバ ファーマシューティカル インダストリーズ リミティド アリスキレン化合物の固形体
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
US20120220663A1 (en) * 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
CN102617392B (zh) * 2011-01-28 2015-04-01 博瑞生物医药技术(苏州)有限公司 一种阿利克仑半富马酸盐晶型ⅰ的制备方法
ITMI20111291A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato etil acetato solvato
ITMI20111290A1 (it) 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato, forma cristallina e solido amorfo
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
HU228526B1 (hu) * 2000-07-05 2013-03-28 Speedel Pharma Ag Eljárás szubsztituált oktanoil-amid-származékok elõállítására, valamint az elõállításhoz alkalmazott közbensõ termékek
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL198470A0 (en) 2010-02-17
MA30921B1 (fr) 2009-11-02
NZ577320A (en) 2012-01-12
ECSP099385A (es) 2009-07-31
CL2007003194A1 (es) 2008-06-13
GT200900116A (es) 2011-06-07
MX2009004885A (es) 2009-05-19
CN101594857A (zh) 2009-12-02
PE20121179A1 (es) 2012-09-13
CA2668828A1 (en) 2008-05-29
EP2079463A1 (en) 2009-07-22
TN2009000174A1 (en) 2010-10-18
PE20081157A1 (es) 2008-09-26
TW200827326A (en) 2008-07-01
WO2008061622A1 (en) 2008-05-29
CO6180428A2 (es) 2010-07-19
JP2010508370A (ja) 2010-03-18
US20100048716A1 (en) 2010-02-25
CN101594857B (zh) 2012-10-31
AR063560A1 (es) 2009-02-04
ZA200902941B (en) 2010-03-31
AU2007323465B2 (en) 2011-08-04
RU2466982C2 (ru) 2012-11-20
KR20090083918A (ko) 2009-08-04
BRPI0718546A2 (pt) 2013-11-19
AU2007323465A1 (en) 2008-05-29
MY148758A (en) 2013-05-31
RU2009121651A (ru) 2010-12-20
US8119841B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
NO20092102L (no) Krystallinformer av aliskiren hemifumarat
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
CY1110813T1 (el) Χημικες ενωσεις
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DE602006008625D1 (de) Polymermicellen für die arzneistoffzufuhr
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
NO20081719L (no) Displaysammenstillinger og fremgangsmater for displayvisning
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009015390A3 (en) Co-incuating confined microbial communities
ATE457310T1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2009155001A3 (en) Wnt protein signalling inhibitors
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
WO2007125105A3 (en) Benzamide glucokinase activators
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
WO2006099193A3 (en) Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2007133562A3 (en) Monocyclic heteroaryl compounds
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
DK2046715T3 (da) Substituerede 1,3-diphenylpropanderivater, præparater og anvendelser deraf
EP2535058A3 (en) Stabilization of vaccines by lyophilization
HK1137028A1 (en) Phosphadiazine hcv polymerase inhibitors iv
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application